Literature DB >> 1840227

5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.

M B Tyers1.   

Abstract

5-HT3 receptors have been the focus of much research during the last decade. They are characterised by being located on neurones both peripherally and centrally; 5-HT3 agonists cause a rapid depolarisation of the membrane potential which results from the opening of cation channels; the 5-HT3 response rapidly desensitizes. 5-HT3 receptors appear to have a modulatory role on other neurotransmitters. The identification of selective agonists and antagonists for this receptor type has allowed the discovery of several important new therapeutic applications. The use of 5-HT3 receptor antagonists in psychoactive illnesses is being explored clinically. In addition, ondansetron, a selective 5-HT3 receptor antagonist, is already being used to prevent the severe nausea and vomiting caused by cancer chemotherapy and radiotherapy. The pharmacological properties of 5-HT3 antagonists are discussed in this chapter.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1840227

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  6 in total

Review 1.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.

Authors:  R M Eglen; C H Lee; W L Smith; L G Johnson; R Clark; R L Whiting; S S Hegde
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

3.  Isoflurane inhibits bronchopulmonary C-fiber-mediated apneic response to phenylbiguanide by depressing 5-HT3 receptor function in anesthetized rats.

Authors:  Zhenxiong Zhang; Jianguo Zhuang; Cancan Zhang; Fadi Xu
Journal:  Neurosci Lett       Date:  2013-07-26       Impact factor: 3.046

4.  5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats.

Authors:  B Arnold; K Allison; S Ivanová; P R Paetsch; T Paslawski; A J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

5.  The Pharmacological Effects of Benachio-F(®) on Rat Gastrointestinal Functions.

Authors:  Bijay Kumar Poudel; Jae Young Yu; Yong Sam Kwon; Hyoung Geun Park; Miwon Son; Joon Ho Jun; Jeong Ah Kim; Jong Oh Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-07-01       Impact factor: 4.634

6.  A Dunnione Compound MB12662 Improves Cisplatin-Induced Tissue Injury and Emesis.

Authors:  Dongsun Park; In Geun Jo; Ja Young Jang; Tae Hwan Kwak; Sang Ku Yoo; Jeong Hee Jeon; Ehn-Kyoung Choi; Seong Soo Joo; Okjin Kim; Yun-Bae Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-09-01       Impact factor: 4.634

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.